S ruxolitinib

Manufactured by Selleck Chemicals

Sourced in Germany

S-Ruxolitinib is a chemical compound used in laboratory research. It is a selective inhibitor of the Janus kinase (JAK) enzymes.

Automatically generated - may contain errors

Lab products found in correlation

Tofacitinib, by Selleck Chemicals (1 mentions) Il 13, by Selleck Chemicals (1 mentions) Pf 04691502, by Selleck Chemicals (1 mentions) Gemcitabine, by Selleck Chemicals (1 mentions) Trametinib, by Selleck Chemicals (1 mentions) Gdc0032, by Selleck Chemicals (1 mentions) Panobinostat, by Selleck Chemicals (1 mentions) Dinaciclib, by Selleck Chemicals (1 mentions) Trichostatin a, by Selleck Chemicals (1 mentions) Sp2509, by Selleck Chemicals (1 mentions) Bgj398, by Targetmol (1 mentions)

Spelling variants of this product

Ruxolitinib (206 citations)

3 protocols using s ruxolitinib

Cytokine-mediated Signaling Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

IL-4 and IL-13 were obtained from Merck Millipore, Darmstadt, Germany. S-.Ruxolitinib and Tofacitinib, both were obtained from Selleckchem, distributed by Absource Diagnostics, Munich, Germany. If not mentioned otherwise, IL-13 was added at a concentration of 10 ng/mL. S-Ruxolitinib and Tofacitinib was used at concentrations of 2.5 µM each.

Schmidt H., Braubach P., Schilpp C., Lochbaum R., Neuland K., Thompson K., Jonigk D., Frick M., Dietl P, & Wittekindt O.H. (2019). IL-13 Impairs Tight Junctions in Airway Epithelia. International Journal of Molecular Sciences, 20(13), 3222.

+ Open protocol

+ Expand

Ruxolitinib Stability in Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

JAK inhibitor S-Ruxolitinib (dual JAK1/2 inhibitor tool compound) was purchased from selleck (http://www.selleck.cn/). Owing to the instability of the compound, the medium with inhibitor was replaced every 5 days.

Fan Y., Yue J., Xiao M., Han-Zhang H., Wang Y.V., Ma C., Deng Z., Li Y., Yu Y., Wang X., Niu S., Hua Y., Weng Z., Atadja P., Li E, & Xiang B. (2017). FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion. eLife, 6, e26129.

+ Open protocol

+ Expand

Evaluating Small Molecule Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pemigatinib (Cat# T12401), BGJ398 (infigratinib, Cat# T1975) and quisinostat (Cat# T6055) were purchased from TargetMol Chemicals (Boston, MA). Gemcitabine (Cat# LY-188011), panobinostat (Cat# LBH589), T6061 (LMK-235, Cat# S7569), trichostatin A (Cat# S1045), PF-04691502 (Cat# S2743), GDC-0032 (Taselisib, Cat# S7103), ciclopriox olamine (Cat# S3019), S-Ruxolitinib (Cat# A2902), SP2509 (Cat# S7680), dinaciclib (Cat# S2768), and Trametinib (Cat# S2673) were purchased from Selleck Chemicals (Houston, TX).

Lidsky M.E., Wang Z., Lu M., Liu A., Hsu S.D., McCall S.J., Sheng Z., Granek J.A., Owzar K., Anderson K.S, & Wood K.C. (2022). Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. NPJ Precision Oncology, 6, 75.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!